Umbilical cord blood therapy potentiated with erythropoietin for children with cerebral palsy: a double-blind, randomized, placebo-controlled trial
Kyunghoon Min, Junyoung Song, Jin Young Kang, Jooyeon Ko, Ju Seok Ryu, Myung Seo Kang, Su Jin Jang, Sang Heum Kim, Doyeun Oh, Moon Kyu Kim, Sung Soo Kim, Minyoung Kim, Kyunghoon Min, Junyoung Song, Jin Young Kang, Jooyeon Ko, Ju Seok Ryu, Myung Seo Kang, Su Jin Jang, Sang Heum Kim, Doyeun Oh, Moon Kyu Kim, Sung Soo Kim, Minyoung Kim
Abstract
Allogeneic umbilical cord blood (UCB) has therapeutic potential for cerebral palsy (CP). Concomitant administration of recombinant human erythropoietin (rhEPO) may boost the efficacy of UCB, as it has neurotrophic effects. The objectives of this study were to assess the safety and efficacy of allogeneic UCB potentiated with rhEPO in children with CP. Children with CP were randomly assigned to one of three parallel groups: the pUCB group, which received allogeneic UCB potentiated with rhEPO; the EPO group, which received rhEPO and placebo UCB; and the Control group, which received placebo UCB and placebo rhEPO. All participants received rehabilitation therapy. The main outcomes were changes in scores on the following measures during the 6 months treatment period: the gross motor performance measure (GMPM), gross motor function measure, and Bayley scales of infant development-II (BSID-II) Mental and Motor scales (18). F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET/CT) and diffusion tensor images (DTI) were acquired at baseline and followed up to detect changes in the brain. In total, 96 subjects completed the study. Compared with the EPO (n = 33) and Control (n = 32) groups, the pUCB (n = 31) group had significantly higher scores on the GMPM and BSID-II Mental and Motor scales at 6 months. DTI revealed significant correlations between the GMPM increment and changes in fractional anisotropy in the pUCB group. 18F-FDG-PET/CT showed differential activation and deactivation patterns between the three groups. The incidence of serious adverse events did not differ between groups. In conclusion, UCB treatment ameliorated motor and cognitive dysfunction in children with CP undergoing active rehabilitation, accompanied by structural and metabolic changes in the brain.
Copyright © 2012 AlphaMed Press.
Figures
References
- Bax M, Goldstein M, Rosenbaum P, et al. Proposed definition and classification of cerebral palsy. Dev Med Child Neurol. 2005;47:571–576.
- Aisen ML, Kerkovich D, Mast J, et al. Cerebral palsy: Clinical care and neurological rehabilitation. Lancet Neurol. 2011;10:844–852.
- Patel DR, Greydanus DE, Calles JL, Jr, et al. Developmental disabilities across the lifespan. Dis Mon. 2010;56:304–397.
- Carroll JE, Mays RW. Update on stem cell therapy for cerebral palsy. Expert Opin Biol Ther. 2011;11:463–471.
- Lee MW, Jang IK, Yoo KH, et al. Stem and progenitor cells in human umbilical cord blood. Int J Hematol. 2010;92:45–51.
- Gluckman E, Broxmeyer HA, Auerbach AD, et al. Hematopoietic reconstitution in a patient with Fanconi's anemia by means of umbilical-cord blood from an HLA-identical sibling. N Engl J Med. 1989;321:1174–1178.
- Kurtzberg J. Update on umbilical cord blood transplantation. Curr Opin Pediatr. 2009;21:22–29.
- Vendrame M, Cassady J, Newcomb J, et al. Infusion of human umbilical cord blood cells in a rat model of stroke dose-dependently rescues behavioral deficits and reduces infarct volume. Stroke. 2004;35:2390–2395.
- Nan Z, Grande A, Sanberg CD, et al. Infusion of human umbilical cord blood ameliorates neurologic deficits in rats with hemorrhagic brain injury. Ann N Y Acad Sci. 2005;1049:84–96.
- Lu D, Sanberg PR, Mahmood A, et al. Intravenous administration of human umbilical cord blood reduces neurological deficit in the rat after traumatic brain injury. Cell Transplant. 2002;11:275–281.
- Nikolic WV, Hou H, Town T, et al. Peripherally administered human umbilical cord blood cells reduce parenchymal and vascular beta-amyloid deposits in Alzheimer mice. Stem Cells Dev. 2008;17:423–439.
- Meier C, Middelanis J, Wasielewski B, et al. Spastic paresis after perinatal brain damage in rats is reduced by human cord blood mononuclear cells. Pediatr Res. 2006;59:244–249.
- Papadopoulos KI, Low SS, Aw TC, et al. Safety and feasibility of autologous umbilical cord blood transfusion in 2 toddlers with cerebral palsy and the role of low dose granulocyte-colony stimulating factor injections. Restor Neurol Neurosci. 2011;29:17–22.
- Sun J, Allison J, McLaughlin C, et al. Differences in quality between privately and publicly banked umbilical cord blood units: A pilot study of autologous cord blood infusion in children with acquired neurologic disorders. Transfusion. 2010;50:1980–1987.
- Cox CS, Jr, Baumgartner JE, Harting MT, et al. Autologous bone marrow mononuclear cell therapy for severe traumatic brain injury in children. Neurosurgery. 2011;68:588–600.
- Liu WS, Chen CT, Foo NH, et al. Human umbilical cord blood cells protect against hypothalamic apoptosis and systemic inflammation response during heatstroke in rats. Pediatr Neonatol. 2009;50:208–216.
- Vexler ZS, Yenari MA. Does inflammation after stroke affect the developing brain differently than adult brain? Dev Neurosci. 2009;31:378–393.
- Lin CY, Chang YC, Wang ST, et al. Altered inflammatory responses in preterm children with cerebral palsy. Ann Neurol. 2010;68:204–212.
- Escolar ML, Poe MD, Provenzale JM, et al. Transplantation of umbilical-cord blood in babies with infantile Krabbe's disease. N Engl J Med. 2005;352:2069–2081.
- Sorror ML, Maris MB, Storer B, et al. Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: Influence of pretransplantation comorbidities. Blood. 2004;104:961–968.
- Jing M, Shingo T, Yasuhara T, et al. The combined therapy of intrahippocampal transplantation of adult neural stem cells and intraventricular erythropoietin-infusion ameliorates spontaneous recurrent seizures by suppression of abnormal mossy fiber sprouting. Brain Res. 2009;1295:203–217.
- Luo J, Zhang HT, Jiang XD, et al. Combination of bone marrow stromal cell transplantation with mobilization by granulocyte-colony stimulating factor promotes functional recovery after spinal cord transection. Acta Neurochir (Wien) 2009;151:1483–1492.
- Chen J, Li Y, Chopp M. Intracerebral transplantation of bone marrow with BDNF after MCAo in rat. Neuropharmacology. 2000;39:711–716.
- Wustenberg T, Begemann M, Bartels C, et al. Recombinant human erythropoietin delays loss of gray matter in chronic schizophrenia. Mol Psychiatry. 2011;16:26–36. 1.
- Siren AL, Fasshauer T, Bartels C, et al. Therapeutic potential of erythropoietin and its structural or functional variants in the nervous system. Neurotherapeutics. 2009;6:108–127.
- Iwai M, Cao G, Yin W, et al. Erythropoietin promotes neuronal replacement through revascularization and neurogenesis after neonatal hypoxia/ischemia in rats. Stroke. 2007;38:2795–2803.
- Iwai M, Stetler RA, Xing J, et al. Enhanced oligodendrogenesis and recovery of neurological function by erythropoietin after neonatal hypoxic/ischemic brain injury. Stroke. 2010;41:1032–1037.
- Keogh CL, Yu SP, Wei L. The effect of recombinant human erythropoietin on neurovasculature repair after focal ischemic stroke in neonatal rats. J Pharmacol Exp Ther. 2007;322:521–528.
- Liu W, Shen Y, Plane JM, et al. Neuroprotective potential of erythropoietin and its derivative carbamylated erythropoietin in periventricular leukomalacia. Exp Neurol. 2011;230:227–239.
- van der Kooij MA, Groenendaal F, Kavelaars A, et al. Neuroprotective properties and mechanisms of erythropoietin in in vitro and in vivo experimental models for hypoxia/ischemia. Brain Res Rev. 2008;59:22–33.
- Dasari VR, Veeravalli KK, Saving KL, et al. Neuroprotection by cord blood stem cells against glutamate-induced apoptosis is mediated by Akt pathway. Neurobiol Dis. 2008;32:486–498.
- Rubinstein P, Dobrila L, Rosenfield RE, et al. Processing and cryopreservation of placental/umbilical cord blood for unrelated bone marrow reconstitution. Proc Natl Acad Sci USA. 1995;92:10119–10122.
- Boyce WF, Gowland C, Rosenbaum PL, et al. The gross motor performance measure: Validity and responsiveness of a measure of quality of movement. Phys Ther. 1995;75:603–613.
- Russell DJ, Rosenbaum PL, Avery LM, et al. Gross Motor Function Measure (GMFM-66 & GMFM-88) User's Manual. London: Mac Keith Press; 2002.
- Bayley N. Bayley Scales of Infant Development. San Antonio, TX: The Psychological Corporation; 1993.
- Haley SM, Coster WJ, Ludlow LH, et al. Pediatric Evaluation of Disability Inventory (PEDI) Boston, MA: PEDI Research Group; 1992.
- Uniform Data System for Medical Rehabilitation. Guide for the Uniform Data Set for Medical Rehabilitation for Children (WeeFIM) Buffalo, NY: State University of New York; 1993.
- DeMatteo CLM, Russell D, Pollock N, et al. QUEST: Quality of Upper Extremity Skills Test Manual. Hamilton, ON: Neurodevelopmental Research Unit, Chedoke Campus, Chedoke-McMasters Hospital; 1992.
- Nagae LM, Hoon AH, Jr, Stashinko E, et al. Diffusion tensor imaging in children with periventricular leukomalacia: Variability of injuries to white matter tracts. Am J Neuroradiol. 2007;28:1213–1222.
- Hong JH, Son SM, Jang SH. Identification of spinothalamic tract and its related thalamocortical fibers in human brain. Neurosci Lett. 2010;468:102–105.
- Ashwal S, Russman BS, Blasco PA, et al. Practice parameter: Diagnostic assessment of the child with cerebral palsy: Report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology. 2004;62:851–863.
- .
- Norvatis. Available at . Accessed Sep 30, 2012.
- Martinez-Biarge M, Diez-Sebastian J, Rutherford MA, et al. Outcomes after central grey matter injury in term perinatal hypoxic-ischaemic encephalopathy. Early Hum Dev. 2010;86:675–682.
- Statler PA, McPherson RJ, Bauer LA, et al. Pharmacokinetics of high-dose recombinant erythropoietin in plasma and brain of neonatal rats. Pediatr Res. 2007;61:671–675.
- Lapchak PA, Kirkeby A, Zivin JA, et al. Therapeutic window for nonerythropoietic carbamylated-erythropoietin to improve motor function following multiple infarct ischemic strokes in New Zealand white rabbits. Brain Res. 2008;1238:208–214.
- Walker PA, Shah SK, Jimenez F, et al. Bone marrow-derived stromal cell therapy for traumatic brain injury is neuroprotective via stimulation of non-neurologic organ systems. Surgery. 2012;152:790–793.
- Scheck SM, Boyd RN, Rose SE. New insights into the pathology of white matter tracts in cerebral palsy from diffusion magnetic resonance imaging: A systematic review. Dev Med Child Neurol. 2012;54:684–696.
- Yamamoto M, Koshimura K, Kawaguchi M, et al. Stimulating effect of erythropoietin on the release of dopamine and acetylcholine from the rat brain slice. Neurosci Lett. 2000;292:131–133.
- Hershey T, Black KJ, Carl JL, et al. Dopa-induced blood flow responses in nonhuman primates. Exp Neurol. 2000;166:342–349.
- Mishina M, Senda M, Ishii K, et al. Cerebellar activation during ataxic gait in olivopontocerebellar atrophy: A PET study. Acta Neurol Scand. 1999;100:369–376.
- Lee JD, Kim DI, Ryu YH, et al. Technetium-99m-ECD brain SPECT in cerebral palsy: Comparison with MRI. J Nucl Med. 1998;39:619–623.
- Gornicka-Pawlak el B, Janowski M, Habich A, et al. Systemic treatment of focal brain injury in the rat by human umbilical cord blood cells being at different level of neural commitment. Acta Neurobiol Exp (Wars) 2011;71:46–64.
- Sullivan PG, Thompson M, Scheff SW. Continuous infusion of cyclosporin A postinjury significantly ameliorates cortical damage following traumatic brain injury. Exp Neurol. 2000;161:631–637.
- Han W, Ming M, He TC, et al. Immunosuppressive cyclosporin A activates AKT in keratinocytes through PTEN suppression: Implications in skin carcinogenesis. J Biol Chem. 2010;285:11369–11377.
- Yuen CM, Sun CK, Lin YC, et al. Combination of cyclosporine and erythropoietin improves brain infarct size and neurological function in rats after ischemic stroke. J Transl Med. 2011;9:141.
- Gijtenbeek JM, van den Bent MJ, Vecht CJ. Cyclosporine neurotoxicity: A review. J Neurol. 1999;246:339–346.
Source: PubMed